Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston ready for cardiovascular surgery sell-off?

This article was originally published in Clinica

Executive Summary

Boston Scientific is on the verge of selling its cardiac surgery and vascular surgery businesses, as part of a strategy to strengthen its finances. Boston thus has three of its business units on the market - it recently revealed that it is considering the divestment of its fluid management business - and is in talks with potential buyers for them. The company hopes the proceeds will cover the loss of revenue generated by each business. Total revenue for the cardiac and vascular units in fiscal 2006 was $275m. The Natick, Massachusetts-based firm acquired the cardiac surgery business through its purchase of Guidant. The unit has a manufacturing facility in Puerto Rico, with 450 employees, and makes clampless surgery systems, beating-heart surgery systems, endoscopic vessel-harvesting systems and microwave ablation systems. The vascular unit manufactures grafts and patches for treating abdominal aortic aneurysms, at its Wayne, New Jersey plant, and has 250 members of staff. Boston has been weighed down with debt after purchasing Guidant for $27bn in April 2006 (see Clinica No 1203, p 2), and is looking to sell two manufacturing plants in Glens Falls, New York, and Tullamore, Ireland (see Clinica No 1268, p 10), as well as the three business units.

You may also be interested in...

Canada Allows Exceptional Drug, Device Imports To Tackle COVID-19 Shortages

Medical products that do not fully comply with Canadian requirements but are manufactured according to comparable standards are being allowed into the country to deal with COVID-19-related shortages.

RECOVERY Coronavirus Study ‘Will Attract Global Players To UK’

A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.

Warning Letter Roundup & Recap – 8 April 2020

Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts